aTyr Pharma, Inc. (ATYR)
0.4851
-0.02
(-3.65%)
USD |
NASDAQ |
Sep 04, 11:30
aTyr Pharma Net Income (Quarterly) : -10.31M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.31M |
| March 31, 2026 | -10.79M |
| December 31, 2025 | -13.96M |
| September 30, 2025 | -25.75M |
| June 30, 2025 | -19.53M |
| March 31, 2025 | -14.88M |
| December 31, 2024 | -14.97M |
| September 30, 2024 | -17.26M |
| June 30, 2024 | -16.31M |
| March 31, 2024 | -15.49M |
| December 31, 2023 | -14.76M |
| September 30, 2023 | -11.34M |
| June 30, 2023 | -12.34M |
| March 31, 2023 | -11.95M |
| December 31, 2022 | -7.523M |
| September 30, 2022 | -13.24M |
| June 30, 2022 | -12.42M |
| March 31, 2022 | -12.15M |
| December 31, 2021 | -8.561M |
| September 30, 2021 | -7.669M |
| June 30, 2021 | -10.39M |
| March 31, 2021 | -7.155M |
| December 31, 2020 | -4.935M |
| Date | Value |
|---|---|
| September 30, 2020 | -6.60M |
| June 30, 2020 | -6.447M |
| March 31, 2020 | 1.752M |
| December 31, 2019 | -6.133M |
| September 30, 2019 | -5.645M |
| June 30, 2019 | -5.848M |
| March 31, 2019 | -6.137M |
| December 31, 2018 | -6.322M |
| September 30, 2018 | -7.114M |
| June 30, 2018 | -10.41M |
| March 31, 2018 | -10.67M |
| December 31, 2017 | -11.47M |
| September 30, 2017 | -11.19M |
| June 30, 2017 | -12.14M |
| March 31, 2017 | -13.40M |
| December 31, 2016 | -12.57M |
| September 30, 2016 | -13.82M |
| June 30, 2016 | -15.38M |
| March 31, 2016 | -16.09M |
| December 31, 2015 | -16.49M |
| September 30, 2015 | -11.33M |
| June 30, 2015 | -11.08M |
| March 31, 2015 | -9.071M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| MetaVia, Inc. | -5.316M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 10.31M |
| EPS Diluted (Quarterly) | -0.1051 |
| Enterprise Value | 3.074M |
| Earnings Yield | -128.4% |
| Normalized Earnings Yield | -128.34 |